CN105567739A - 病毒载体颗粒及其构建方法和应用 - Google Patents
病毒载体颗粒及其构建方法和应用 Download PDFInfo
- Publication number
- CN105567739A CN105567739A CN201610077434.0A CN201610077434A CN105567739A CN 105567739 A CN105567739 A CN 105567739A CN 201610077434 A CN201610077434 A CN 201610077434A CN 105567739 A CN105567739 A CN 105567739A
- Authority
- CN
- China
- Prior art keywords
- novain
- cell
- particles
- vector particles
- pwpi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002245 particle Substances 0.000 title claims abstract description 60
- 241000700605 Viruses Species 0.000 title claims abstract description 16
- 238000010276 construction Methods 0.000 title claims abstract description 13
- 102000004190 Enzymes Human genes 0.000 claims abstract description 26
- 108090000790 Enzymes Proteins 0.000 claims abstract description 26
- 238000011282 treatment Methods 0.000 claims abstract description 21
- 208000002193 Pain Diseases 0.000 claims abstract description 19
- 238000001890 transfection Methods 0.000 claims abstract description 11
- 208000000094 Chronic Pain Diseases 0.000 claims abstract description 9
- 239000007788 liquid Substances 0.000 claims abstract description 9
- 210000002966 serum Anatomy 0.000 claims abstract description 7
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims abstract description 4
- 244000309466 calf Species 0.000 claims abstract description 4
- PHIQHXFUZVPYII-UHFFFAOYSA-N carnitine Chemical compound C[N+](C)(C)CC(O)CC([O-])=O PHIQHXFUZVPYII-UHFFFAOYSA-N 0.000 claims description 63
- 239000013598 vector Substances 0.000 claims description 31
- 239000013612 plasmid Substances 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 17
- 239000000243 solution Substances 0.000 claims description 13
- 230000008569 process Effects 0.000 claims description 12
- 235000015097 nutrients Nutrition 0.000 claims description 9
- 201000008482 osteoarthritis Diseases 0.000 claims description 5
- 238000003151 transfection method Methods 0.000 claims description 5
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 3
- 239000001506 calcium phosphate Substances 0.000 claims description 3
- 235000011010 calcium phosphates Nutrition 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 3
- 230000001186 cumulative effect Effects 0.000 claims description 3
- 239000011259 mixed solution Substances 0.000 claims description 3
- 230000003020 moisturizing effect Effects 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 3
- 238000005199 ultracentrifugation Methods 0.000 claims description 3
- 241000702421 Dependoparvovirus Species 0.000 claims description 2
- 241000700584 Simplexvirus Species 0.000 claims description 2
- 229940124583 pain medication Drugs 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 15
- 230000002093 peripheral effect Effects 0.000 abstract description 5
- 210000000653 nervous system Anatomy 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- 238000012258 culturing Methods 0.000 abstract 1
- 239000001963 growth medium Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 56
- 108090000623 proteins and genes Proteins 0.000 description 29
- 229940088598 enzyme Drugs 0.000 description 24
- 102000004604 Vesicle-Associated Membrane Protein 3 Human genes 0.000 description 16
- 108010017749 Vesicle-Associated Membrane Protein 3 Proteins 0.000 description 16
- 210000002437 synoviocyte Anatomy 0.000 description 14
- 210000002569 neuron Anatomy 0.000 description 11
- 239000002516 radical scavenger Substances 0.000 description 11
- 230000028327 secretion Effects 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 10
- 238000005520 cutting process Methods 0.000 description 10
- 230000002757 inflammatory effect Effects 0.000 description 10
- 230000004054 inflammatory process Effects 0.000 description 10
- 230000036407 pain Effects 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 102000000583 SNARE Proteins Human genes 0.000 description 9
- 108010041948 SNARE Proteins Proteins 0.000 description 9
- 230000001537 neural effect Effects 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 210000005036 nerve Anatomy 0.000 description 8
- 230000008058 pain sensation Effects 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 230000006378 damage Effects 0.000 description 7
- 208000004296 neuralgia Diseases 0.000 description 7
- 235000014594 pastries Nutrition 0.000 description 6
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 102000004603 Vesicle-Associated Membrane Protein 1 Human genes 0.000 description 5
- 108010017743 Vesicle-Associated Membrane Protein 1 Proteins 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 230000001953 sensory effect Effects 0.000 description 5
- 102100030552 Synaptosomal-associated protein 25 Human genes 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 210000000929 nociceptor Anatomy 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 210000002504 synaptic vesicle Anatomy 0.000 description 4
- 210000002845 virion Anatomy 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- 108010005730 R-SNARE Proteins Proteins 0.000 description 3
- 108091027967 Small hairpin RNA Proteins 0.000 description 3
- 102000002215 Synaptobrevin Human genes 0.000 description 3
- 108010057722 Synaptosomal-Associated Protein 25 Proteins 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 108091008700 nociceptors Proteins 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102100038518 Calcitonin Human genes 0.000 description 2
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 101150096292 Ppme1 gene Proteins 0.000 description 2
- 108010010469 Qa-SNARE Proteins Proteins 0.000 description 2
- 241000712907 Retroviridae Species 0.000 description 2
- 101710189545 Synaptosomal-associated protein 23 Proteins 0.000 description 2
- 102100030545 Synaptosomal-associated protein 23 Human genes 0.000 description 2
- 102000050389 Syntaxin Human genes 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- MURGITYSBWUQTI-UHFFFAOYSA-N fluorescin Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC=C(O)C=C2OC2=CC(O)=CC=C21 MURGITYSBWUQTI-UHFFFAOYSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 229940124636 opioid drug Drugs 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000020341 sensory perception of pain Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- GGRLKHMFMUXIOG-UHFFFAOYSA-M 2-acetyloxyethyl(trimethyl)azanium;hydroxide Chemical compound [OH-].CC(=O)OCC[N+](C)(C)C GGRLKHMFMUXIOG-UHFFFAOYSA-M 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102100021786 CMP-N-acetylneuraminate-poly-alpha-2,8-sialyltransferase Human genes 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 101000616698 Homo sapiens CMP-N-acetylneuraminate-poly-alpha-2,8-sialyltransferase Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 208000001294 Nociceptive Pain Diseases 0.000 description 1
- 101150105440 PME1 gene Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 102100037834 Protein phosphatase methylesterase 1 Human genes 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010039361 Sacroiliitis Diseases 0.000 description 1
- 108010043943 Starch Phosphorylase Proteins 0.000 description 1
- 102000013265 Syntaxin 1 Human genes 0.000 description 1
- 108010090618 Syntaxin 1 Proteins 0.000 description 1
- 206010043269 Tension headache Diseases 0.000 description 1
- 208000008548 Tension-Type Headache Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 102000003786 Vesicle-associated membrane protein 2 Human genes 0.000 description 1
- 108090000169 Vesicle-associated membrane protein 2 Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000798 anti-retroviral effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000004751 neurological system process Effects 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000003594 spinal ganglia Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 102000003137 synaptotagmin Human genes 0.000 description 1
- 108060008004 synaptotagmin Proteins 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000003684 theca cell Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001519 thymoleptic effect Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16041—Use of virus, viral particle or viral elements as a vector
- C12N2710/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610077434.0A CN105567739B (zh) | 2016-02-04 | 2016-02-04 | 病毒载体颗粒及其构建方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610077434.0A CN105567739B (zh) | 2016-02-04 | 2016-02-04 | 病毒载体颗粒及其构建方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105567739A true CN105567739A (zh) | 2016-05-11 |
CN105567739B CN105567739B (zh) | 2019-07-12 |
Family
ID=55878362
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610077434.0A Active CN105567739B (zh) | 2016-02-04 | 2016-02-04 | 病毒载体颗粒及其构建方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105567739B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114134181A (zh) * | 2021-03-02 | 2022-03-04 | 河南大学 | 一种表达单元、重组慢病毒表达载体、重组慢病毒及其制备方法和应用 |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1379679A (zh) * | 1999-10-12 | 2002-11-13 | 阿勒根销售公司 | 治疗疼痛的方法 |
WO2003101483A1 (en) * | 2002-05-31 | 2003-12-11 | Solux Corporation | Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use |
CN1491115A (zh) * | 2001-01-05 | 2004-04-21 | �ڵ��ڴ�ѧ | 肉毒杆菌毒素用于治疗关节病变的用途 |
CN1658897A (zh) * | 2000-10-04 | 2005-08-24 | 阿勒根公司 | 用于治疗肌肉损伤的方法 |
WO2006060044A1 (en) * | 2004-08-02 | 2006-06-08 | Allergan, Inc. | Toxin compounds with enhanced membrane translocation characteristics |
US20090048431A1 (en) * | 2004-06-30 | 2009-02-19 | Allergan, Inc. | Multivalent clostridial toxins |
US20100041098A1 (en) * | 2005-03-15 | 2010-02-18 | Allergan, Inc. | Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells |
US20110070621A1 (en) * | 2006-03-15 | 2011-03-24 | Allergan, Inc. | Multivalent Clostridial Toxins |
WO2011091419A2 (en) * | 2010-01-25 | 2011-07-28 | New York Universiy | Recombinant derivatives of botulinum neurotoxins engineered for trafficking studies and neuronal delivery |
CN103520701A (zh) * | 2013-09-27 | 2014-01-22 | 深圳先进技术研究院 | A型肉毒菌素在制备用于术前预防神经病理性疼痛中的药物中的应用 |
CN103649317A (zh) * | 2011-05-16 | 2014-03-19 | 辛它可辛有限公司 | 治疗性融合蛋白 |
WO2015168562A1 (en) * | 2014-05-01 | 2015-11-05 | Anterios, Inc. | Demonstrable efficacy across or within patient populations |
-
2016
- 2016-02-04 CN CN201610077434.0A patent/CN105567739B/zh active Active
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1379679A (zh) * | 1999-10-12 | 2002-11-13 | 阿勒根销售公司 | 治疗疼痛的方法 |
CN1658897A (zh) * | 2000-10-04 | 2005-08-24 | 阿勒根公司 | 用于治疗肌肉损伤的方法 |
CN1491115A (zh) * | 2001-01-05 | 2004-04-21 | �ڵ��ڴ�ѧ | 肉毒杆菌毒素用于治疗关节病变的用途 |
WO2003101483A1 (en) * | 2002-05-31 | 2003-12-11 | Solux Corporation | Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use |
US20090048431A1 (en) * | 2004-06-30 | 2009-02-19 | Allergan, Inc. | Multivalent clostridial toxins |
WO2006060044A1 (en) * | 2004-08-02 | 2006-06-08 | Allergan, Inc. | Toxin compounds with enhanced membrane translocation characteristics |
US20100041098A1 (en) * | 2005-03-15 | 2010-02-18 | Allergan, Inc. | Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells |
US20110070621A1 (en) * | 2006-03-15 | 2011-03-24 | Allergan, Inc. | Multivalent Clostridial Toxins |
WO2011091419A2 (en) * | 2010-01-25 | 2011-07-28 | New York Universiy | Recombinant derivatives of botulinum neurotoxins engineered for trafficking studies and neuronal delivery |
CN103649317A (zh) * | 2011-05-16 | 2014-03-19 | 辛它可辛有限公司 | 治疗性融合蛋白 |
CN103520701A (zh) * | 2013-09-27 | 2014-01-22 | 深圳先进技术研究院 | A型肉毒菌素在制备用于术前预防神经病理性疼痛中的药物中的应用 |
WO2015168562A1 (en) * | 2014-05-01 | 2015-11-05 | Anterios, Inc. | Demonstrable efficacy across or within patient populations |
Non-Patent Citations (7)
Title |
---|
HIDEYUKI YAMAMOTO1 ET AL: "《Specificity of botulinum protease for human VAMP family proteins》", 《MICROBIOL IMMUNOL》 * |
KI YEON YOO ET AL: "《Anti-inflammatory Effects of Botulinum Toxin Type A in a Complete Freund’s Adjuvant-Induced Arthritic Knee Joint of Hind Leg on Rat Model》", 《NEUROTOX RES》 * |
MAREN L. MAHOWALD ET AL: "《Long Term Effects of Intra-articular Botulinum Toxin A for Refractory Joint Pain》", 《NEUROTOXICITY RESEARCH,》 * |
MAREN LAWSON MAHOWALD ET AL: "《Intra-articular Botulinum Toxin Type A: A new approach to treat》", 《TOXICON》 * |
戴旭东主编: "《中国癌症研究进展》", 31 December 2000 * |
罗进勇: "《鉴定分析与BMP9诱导成骨有关的TGFβ受体》", 《重庆医科大学博士学位论文》 * |
马雯等: "《RYBP慢病毒表达载体的构建及对结肠癌细胞 HCT116 增殖的影响》", 《医学研究杂志》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114134181A (zh) * | 2021-03-02 | 2022-03-04 | 河南大学 | 一种表达单元、重组慢病毒表达载体、重组慢病毒及其制备方法和应用 |
CN114134181B (zh) * | 2021-03-02 | 2024-01-12 | 河南大学 | 一种表达单元、重组慢病毒表达载体、重组慢病毒及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN105567739B (zh) | 2019-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU730305B2 (en) | Therapeutic molecules generated by trans-splicing | |
RU2650811C2 (ru) | Композиции и способы лечения гемоглобинопатии | |
CN107446923A (zh) | rAAV8‑CRISPR‑SaCas9***及在制备乙肝治疗药物中的应用 | |
JP2002500662A (ja) | 核酸と細胞外マトリックスを崩壊させる物質とを組み合わせた遺伝子治療用組合せ製剤 | |
CN102083975A (zh) | 小环dna载体制剂及其制备方法和使用方法 | |
Fletcher et al. | Transgene expression in the striatum following intracerebral injections of DNA nanoparticles encoding for human glial cell line-derived neurotrophic factor | |
EP3610025A1 (en) | Multiple transgene recombinant adenovirus | |
CN110249051A (zh) | 增强功能性髓鞘产生的方法和组合物 | |
CN110747211A (zh) | 基于crispr的改变基因产物表达的方法及其应用 | |
CA2255141A1 (en) | Nucleic acid constructs for gene therapy whose activity is affected by inhibitors of cyclin-dependent kinases | |
CN106167791B (zh) | MSC-TNF α-AB干细胞及其制备方法和应用 | |
US20210363212A1 (en) | Genetically engineered car t cells that secret interleukin-12 and therapeutic uses thereof | |
CN101586096A (zh) | 一种共表达人源谷氨酸脱羧酶和细胞因子的重组病毒 | |
CN103834691A (zh) | 靶向il-33基因rna干扰重组慢病毒载体的构建方法 | |
CN105567739A (zh) | 病毒载体颗粒及其构建方法和应用 | |
Meunier et al. | Lentiviral-mediated targeted transgene expression in dorsal spinal cord glia: tool for the study of glial cell implication in mechanisms underlying chronic pain development | |
CN108866058B (zh) | 靶向KRAS的siRNA及其在制备胰腺癌治疗药物中的应用 | |
Fernández‐Rubio et al. | Regulated expression of murine CD40L by a lentiviral vector transcriptionally targeted through its endogenous promoter | |
CN105779480A (zh) | 一种携带多位点突变型egfr新抗原基因的重组腺相关病毒载体及构建方法和应用 | |
KR20230172786A (ko) | 구제역 바이러스에 저항성을 갖는 itgb8 유전자 편집 세포 및 이의 용도 | |
CN112626068B (zh) | 一种靶向Notch1基因的LncRNA及其应用 | |
CN114134181B (zh) | 一种表达单元、重组慢病毒表达载体、重组慢病毒及其制备方法和应用 | |
KR20130126549A (ko) | 항종양괴사인자 수용체 2를 발현하도록 설계된 미니서클 벡터를 이용한 자가면역질환 치료 | |
US20230382965A1 (en) | Sheep pdgfd, nucleic acids encoding pdgfd and recombinant lentivirus, host cell and use thereof | |
KR101521980B1 (ko) | 미니서클 벡터를 이용하여 tnfr2가 분비되도록 조절된 줄기세포의 확립 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Meng Jianghui Inventor after: Gang Yijin Inventor after: Meng Baoxi Inventor before: Meng Jianghui |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: 450016 No. 709-1, 7th floor, Pioneer Building, 58 Second Avenue, Zhengzhou Economic and Technological Development Zone, Zhengzhou City, Henan Province Patentee after: ZHENGZHOU KEERLIER BIOLOGICAL TECHNOLOGY Co.,Ltd. Address before: 450016 No. 393, 3rd Floor, Incubation Base of Pioneer Park at the Eighth Avenue of Zhengzhou Economic and Technological Development Zone, Zhengzhou City, Henan Province and the Intersection of Jingnan Second Road Patentee before: ZHENGZHOU KEERLIER BIOLOGICAL TECHNOLOGY Co.,Ltd. |
|
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: No. 1313, 13th Floor, Building 6, Zhengshang Huihang Mingzhu, Intersection of Navigation East Road and 17th Street, Zhengzhou Economic and Technological Development Zone, Zhengzhou City, Henan Province, 450000 Patentee after: ZHENGZHOU KEERLIER BIOLOGICAL TECHNOLOGY Co.,Ltd. Address before: Room 709-1, 7th Floor, Chuangye Building, No. 58 Second Street, Zhengzhou Economic and Technological Development Zone, Zhengzhou City, Henan Province, 450016 Patentee before: ZHENGZHOU KEERLIER BIOLOGICAL TECHNOLOGY Co.,Ltd. |